Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant
tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas …

Aim: The aim of this study is to determine the efficacy and safety of the combination therapy
of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration …

Purpose As for local advanced non-small cell lung cancer (NSCLC), synchronous
radiotherapy and chemotherapy is the standard treatment mode. But for patients with …

This study aimed to investigate the prognostic significance of tumor mutation burden (TMB)
among patients with non-small cell lung cancer (NSCLC) who received platinum-based …

Purpose The present study was to investigate the real-world efficacy and safety of anlotinib
monotherapy as third-line therapy for elderly patients with advanced non-small cell lung …

Background The physical tolerance in the advanced non-small cell lung cancer (NSCLC)
patient often deteriorates, with a limited effective rate of the third-line treatment. This study …

Systemic therapies-based combination treatments have been developed rapidly in patients
with advanced hepatocellular carcinoma (HCC). However, there are still a few patients not …

Objective The purpose of this study was to initially investigate the effect of previous
antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients …

Background: This study aimed to investigate the implication of Vascular Endothelial Growth
Factor Receptor 2 (VEGFR2) polymorphism on the prognosis of anlotinib monotherapy …

Objective The purpose of this study was to initially investigate whether previous
antiangiogenic therapy (bevacizumab and endostar) affect the e cacy of anlotinib in patients …